1. Home
  2. CSWC vs CVAC Comparison

CSWC vs CVAC Comparison

Compare CSWC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capital Southwest Corporation

CSWC

Capital Southwest Corporation

HOLD

Current Price

$22.11

Market Cap

1.3B

ML Signal

HOLD

Logo CureVac N.V.

CVAC

CureVac N.V.

HOLD

Current Price

$4.49

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSWC
CVAC
Founded
1961
2000
Country
United States
Germany
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CSWC
CVAC
Price
$22.11
$4.49
Analyst Decision
Buy
Hold
Analyst Count
5
3
Target Price
$23.50
$6.83
AVG Volume (30 Days)
499.0K
1.2M
Earning Date
02-02-2026
11-24-2025
Dividend Yield
11.60%
N/A
EPS Growth
N/A
94.02
EPS
1.62
0.94
Revenue
$217,271,000.00
$83,000,117.00
Revenue This Year
$13.78
N/A
Revenue Next Year
$7.08
$23.71
P/E Ratio
$13.61
$4.78
Revenue Growth
11.39
N/A
52 Week Low
$17.46
$2.48
52 Week High
$23.86
$5.72

Technical Indicators

Market Signals
Indicator
CSWC
CVAC
Relative Strength Index (RSI) 62.03 40.25
Support Level $21.33 $4.26
Resistance Level $22.52 $4.36
Average True Range (ATR) 0.27 0.17
MACD -0.01 -0.00
Stochastic Oscillator 64.03 40.16

Price Performance

Historical Comparison
CSWC
CVAC

About CSWC Capital Southwest Corporation

Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.

About CVAC CureVac N.V.

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Share on Social Networks: